

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
29 September 2005 (29.09.2005)

PCT

(10) International Publication Number
WO 2005/089045 A2

(51) International Patent Classification: **Not classified**

B-1200 Bruxelles (BE). **ROUSSEAU, Michel** [BE/BE];
Avenue Hippocrate 10/1756-1200, B-1200 Bruxelles (BE).

(21) International Application Number:
PCT/IB2005/002063

(74) Agent: **SPORATEC & VIVES**; CEI-Chemin du Cy-
clotron, 6, B-1348 Louvain-la-Neuve (BE).

(22) International Filing Date: 18 March 2005 (18.03.2005)

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/554,859 19 March 2004 (19.03.2004) US

(71) Applicants (for all designated States except US): **UNI-
VERSITE CATHOLIQUE DE LOUVAIN** [BE/BE]; Ave-
nue Hippocrate 10/1756-1200, B-1200 Bruxelles (BE).
CLINIQUE UNIVERSITAIRES SAINT-LUC [BE/BE];
Avenue Hippocrate 10/1756-1200, B-1200 Bruxelles (BE).


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KETELSLEGERS,
Jean-Marie** [BE/BE]; Avenue Hippocrate 10/1756-1200,

[Continued on next page]

(54) Title: PROGNOSTIC METHODS FOR CONGESTIVE HEART FAILURE



(57) Abstract: Provided are methods for predicting survival outcome of an individual suffering from congestive heart failure. In accordance with the method, a patient's survival outcome is determined by taking into consideration the levels of two markers in combination, the combination being more predictive of survival than either marker alone. The markers include endothelin, atrial natriuretic peptide and brain natriuretic peptide, their precursors and fragments thereof. Individuals with congestive heart failure identified as having increased risk of mortality using the methods of the invention are appropriately targeted for more aggressive therapy.

WO 2005/089045 A2



Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.